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Purpose: Prostate cancer screening with PSA is plagued by high rate of
unnecessary prostate biopsies, especially in the “gray zone” (4.0ng/ml e
10.0ng/ml). We introduce a new circulating-tumor-cell (CTC) biomarker
for detection of prostate cancer in patients in the PSA “gray zone” level,
with the clinically veriﬁed potential to substantially decrease the number
of unnecessary prostate biopsies.
Materials and Methods: A total of 97 patients underwent routine prostate
screening including PSA testing and DRE. One tube of blood was drawn for
each patient and sent for CTC analysis in a double blinded study. A subset
of 23 patients with PSA in the 4.0ng/ml e 10.0ng/ml range was selected
with consent to undergo prostate biopsy for comparison with blinded CTC
test results. The CTC test utilized a microﬂuidic platform with EpCAM as
capture antibody. Suspected CTCs were eluted to a membrane chip and
immunoﬂuorently stained with CK18, PSMA and CD45 antibody to
conﬁrm. Positive CTCs are deﬁned as CK18+ or PSMA+ and CD45-.
Results: Prostate cancer was conﬁrmed by biopsy in 60 out of 97 patients.
CTC assay reported 83% of the cancer cases, demonstrating prostate cancer
detection ability of the assay. In the subset category of 23 patients (PSA in
the 4.0ng/ml e 10.0ng/ml range, and prostate biopsy), the CTC assay was
able to detect cancer in 100% of the prostate cancer cases.
Conclusion: This CTC-based blood test is a valuable new tool in effective
screening for prostate cancer. We have demonstrated that this new CTC
biomarker is able to reduce unnecessary invasive prostate biopsies in the
PSA “gray zone” by over 60%, with the potential to reduce cost to the
system and reduce complication rates due to prostate biopsies, thus
improving patient outcomes.
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Purpose: Urothelial carcinoma (UC) is the most common malignancy
involving urinary bladder (UB) and upper urinary tract (UT) for which the
theranostic markers remain under-investigated. Increasing evidence has
shown that protein tyrosine phosphatases (PTPs) play dominant roles in
setting the levels of tyrosine phosphorylation and promote oncogenic
processes. However, their expression has not been systemically investi-
gated in UC, and our aim is to examine their potential impact on UC.
Materials and Methods: We performed data mining from a published
transcriptome of UBUCs (GSE32894), and PTP type IVA member 3 (PTP4A3)
was identiﬁed as the most signiﬁcantly upregulated gene among those
related to prenylated PTP activity (GO: 0004727). The importance of PTP4A3
was initially analyzed in paired normal urothelium, non-invasive UC, inva-
sive UC, and nodal metastatic tissue. PTP4A3 transcript level was assessed in
snap-frozen UC samples by laser capture microdissection and real-time RT-
PCR. PTP4A3 protein expressionwas determined by immunohistochemistry
in 295 UBUCs and 340 UTUCs, respectively. The association of PTP4A3
expressionwith clinicopathological features, disease-speciﬁc survival (DSS),
and metastasis-free survival (MeFS) was further evaluated.
Results: For both UBUC and UTUC, the level of PTP4A3 signiﬁcantly
increased from normal urothelium, non-invasive UC, invasive UC, to nodal
metastatic tissue (both p< 0.001). The PTP4A3 transcript level was also
markedly upregulated in high stage UC (UBUC, p< 0.001; UTUC,
p¼ 0.002). Overexpression of PTP4A3 protein was signiﬁcantly associated
with advanced pT status, nodal metastasis, and lymphovascular invasion
(all p< 0.001). PTP4A3 overexpression not only predicted worse DSS and
MeFS on univariate analysis (all p< 0.001), but also implicated in inferior
DSS (UBUC, p< 0.001; UTUC, p¼ 0.001) andMeFS (UBUC, p¼ 0.003; UTUC,
p¼ 0.001) on multivariate analysis.
Conclusion: PTP4A3 overexpression independently predicted metastasis
and outcome of both UBUC and UTUC, suggesting its potential theranostic
value in UC.
PD1-3:
THE PROGNOSTIC SIGNIFICANCE OF INFLAMMATION-ASSOCIATED
BLOOD CELL MARKERS IN PATIENTS WITH UPPER TRACT UROTHELIAL
CARCINOMA
Hsin-Chih Yeh 1,2,3, Wen-Jeng Wu1,2,3, Ching-Chia Li 1,2,3, Chun-Nung
Huang 2, Hung-Lung Ke 2,3, Wei-Ming Li 2,3,4, Hsiang-Ying
Lee 1,2,3. 1Department of Urology, Kaohsiung Municipal Ta-Tung Hospital,
Kaohsiung, Taiwan; 2Department of Urology, Kaohsiung Medical University
Hospital, Kaohsiung, Taiwan; 3Graduate Institute of Medicine, College of
Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; 4Department
of Urology, Ministry of Health and Welfare Pingtung Hospital, Pingtung,
Taiwan
Purpose: Inﬂammation-related parameters based on blood cells, including
white blood cell (WBC) count, neutrophil-lymphocyte ratio, platelet count,
and red cell distributionwidth (RDW),have been shown to be associatedwith
prognosis in many cancers. We aimed to evaluate these inﬂammation-asso-
ciated markers simultaneously in upper tract urothelial carcinoma (UTUC).
Materials and Methods: A total of 195 patients with UTUC who received
radical nephroureterectomy between 2005 and 2010 were included
